Galenica Sustainability and Business Performance
About Galenica
Market environment
Business performance
Governance
Sustainability
Outlook
Performance overview Galenica Group
Sales growth in all business areas
Net sales (in million CHF)
H1 2022
H1 2021
change
Local Pharmacies
628
617
+1.8%
Pharmacies at Home
253
218
+16.1%
Strong sales
growth of OTC
medications
ANTI
NATURE
Retail (B2C)
880
834
+5.5%
Continued sales
growth in the area
of rare diseases
Products & Brands
75
60
+26.0%
Services for Professionals
34
29
+18.3%
Professionals (B2B)
109
89
+23.5%
M&A
Products & Care
987
919
+7.4%
Wholesale
1'379
1'329
+3.8%
Logistics & IT Services
64
51
+26.2%
Logistics & IT
1'435
_ 1'378
+4.1%
08/08/22
50
Market share
gains in
wholesale
ANT
Algifor
Liquid caps 400
Ibuprofen 400 mg
VERFORA
FTE
VICKS
VapoRub
VICKS
VapoRub
MEDI SERVICE
Apotheke Farmacia Pharmacie
Lifestage
SOLUTIONS
SPAGYROS
Vitamin
D3 Wild
Of
SARS-CoV-2 Rapid Antigen Test
+
COVID-19
Initiatives
SARS-CoV-2 Rapid Antigen Test
SARS-Coll Raid Astigen"
GALENICA
25View entire presentation